Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.34 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM4B | O94953 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239967 | 0.69 | CYP2A6 (0.43) | ALDH1A1KDM4ELMNAMAPTMEN1 | |
| SCHEMBL28990871 | 0.68 | — | — | |
| SCHEMBL978863 | 0.68 | — | — | |
| SCHEMBL16247101 | 0.68 | ADORA2A (0.34) | ADORA2AADORA1ALDH1A1KDM4EMAPT | |
| SCHEMBL28456334 | 0.68 | NPC1 (0.47) | ADORA2AADORA1ALDH1A1KDM4EMAPT | |
| SCHEMBL4341894 | 0.67 | NOTUM (0.78) | NOTUMALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL245183 | 0.67 | KDM4E (0.39) | ADORA2AADORA1NOTUMALDH1A1KDM4E | |
| SCHEMBL1802262 | 0.66 | MAPK1 (0.40) | ALDH1A1KDM4ELMNAMAPTMEN1 | |
| SCHEMBL4341886 | 0.66 | MAPK1 (0.67) | ADORA2AADORA1NOTUMALDH1A1KDM4E | |
| SCHEMBL5674957 | 0.65 | CYP3A4 (0.48) | NOTUMALDH1A1LMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822925-B1 | CF3O-CONTAINING ENAMINOKETONES AND THEIR UTILIZATION FOR THE PREPARATION OF CF3O-CONTAINING PYRAZOLES | BAYER CROPSCIENCE AG (DE) | 2018-09-05 | — | — | EP | disclosed |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-9745339-B2 | Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| US-9096535-B2 | CF3O-containing enaminoketones and their utilization for the preparation of CF3O-containing pyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| CN-104395335-A | Ligands for antibody and fc-fusion protein purification by affinity chromotography iv | GRAFFINITY PHARMACEUTICALS GMBH | 2015-03-04 | — | — | CN | disclosed |
| EP-2822925-A1 | CF3O-CONTAINING ENAMINOKETONES AND THEIR UTILIZATION FOR THE PREPARATION OF CF3O-CONTAINING PYRAZOLES | Bayer Intellectual Property GmbH (DE) | 2015-01-14 | — | — | EP | disclosed |
| EP-2812346-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | Graffinity Pharmaceuticals GmbH (DE) | 2014-12-17 | — | — | EP | disclosed |
| WO-2014020152-A1 | LIGANDS FOR APHERESIS AND IMMUNOABSORPTION | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| WO-2013120876-A1 | CF3O-containing enaminoketones and their utilization for the preparation of CF3O-containing pyrazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-22 | — | — | WO | disclosed |
| EP-2628722-A1 | CF3O-containing enaminoketones and their utilization for the preparation of CF3O-containing pyrazoles | Bayer CropScience AG (DE) | 2013-08-21 | — | — | EP | disclosed |
| WO-2013117707-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-08-15 | — | — | WO | disclosed |
| EP-1349552-A1 | PYRAZOLO 3,4-D]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055082-A1 | PYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| US-4093812-A | MICROBIOCIDES, DISINFECTANTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | ADORA2A 1234/4885ADORA1 1018/4885NOTUM 4805/4885 |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | ADORA2A 1444/4885ADORA1 1180/4885NOTUM 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.